Sökresultat

Se den nya filmen om sjukhusfysikerutbildningen!

https://www.msf.lu.se/artikel/ny-film-om-sjukhusfysikerutbildningen - 2025-11-17

A study at Lund University reveals that traumatic brain injury alters the small vessels in the brain, resulting in an accumulation of amyloid beta — a hallmark of Alzheimer’s disease. The findings suggest that vascular dysfunction could be an early driver in neurodegenerative disorders rather than being caused by neuronal damage. The study is published in Acta Neuropathologica. An increased risk o

https://www.multipark.lu.se/article/cracking-alzheimers-code-how-brain-trauma-triggers-disease - 2025-11-17

This year, MultiPark has the pleasure of welcoming two new research groups. The Mackenzie Lab aims to decode the neurobiological underpinnings of emotion through experimental studies in animal models. Jacob Vogel’s team uses AI to analyze clinical data for improved understanding as well as patient-tailored diagnosis and care of neurodegenerative disease patients. Say hello to Åsa Mackenzie and Jac

https://www.multipark.lu.se/article/multipark-grows-new-research-groups - 2025-11-17

What role does an inflammatory protein have in disease development? Which neuronal circuits cause different symptoms? How may diabetes affect Parkinson’s disease? Can motor signs be identifies early in individuals at risk for the disease? And how should patients in very advanced disease stages be treated to maintain their quality of life? These questions may soon have answers thanks to several ong

https://www.multipark.lu.se/article/molecule-patient-six-promising-projects-advance-parkinsons-research - 2025-11-17

Researchers at Lund University and Washington University have identified a blood marker that reflects the amount of Alzheimer’s pathology in the brain. This discovery may play a key role in determining who is most likely to benefit from the new Alzheimer’s drugs. In brief:A newly discovered blood marker, MTBR-tau243, can reveal how much Alzheimer’s disease pathology is present in the brain. The hi

https://www.multipark.lu.se/article/new-reliable-blood-marker-reveals-extent-alzheimers-pathology-brain - 2025-11-17

A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led by Lund University in Sweden. “This is a major step in bringing simple blood tests for Alzheimer’s disease into the healthcare system globally,” say the researchers behind the study. In brief:The blood-based marker (P-tau217) may start to change several years before the onset of Al

https://www.multipark.lu.se/article/more-opportunities-test-alzheimers-using-new-analytical-method - 2025-11-17

Meet our scientist Gesine Paul-Visse to learn what happens at the interface where the brain and the body meet: the blood-brain barrier. Here, a very specialized cell, the pericyte, protects the brain and responds strongly to disease. Gesine Paul-Visse leads Translational Neurology, one of MultiPark’s research groups. As both a neurologist and a researcher, she has focused on neurodegeneration for

https://www.multipark.lu.se/article/meet-our-scientists-podcast-gesine-paul-visse-about-brains-frontline - 2025-11-17

Researchers at MultiPark have uncovered in mice how the protein TDP-43, known for its role in several neurodegenerative diseases, disrupts the hypothalamus, the brain’s key center for metabolic control. Their study sheds new light on the role of TDP-43 in metabolic and psychiatric symptoms shared across frontotemporal dementia, Huntington’s disease, and ALS – findings that could support the develo

https://www.multipark.lu.se/article/protein-mismanagement-brains-control-center-fuels-early-symptoms-neurodegenerative-diseases - 2025-11-17

An experimental study from Lund University reveals for the first time that different Parkinson’s medications affect brain activity in distinct ways. This could explain why some patients develop impulsive and compulsive behaviors as a result of their treatment. The findings have been published in NPJ Parkinson’s Disease. Upon receiving treatment for their motor symptoms, many patients with Parkinso

https://www.multipark.lu.se/article/brain-activation-pattern-behind-impulsivity-parkinsons-treatment-discovered - 2025-11-17

Meet our scientist, Dr. Niklas Mattsson-Carlgren! He explains why studying biomarkers is essential to advancing Alzheimer’s research. Niklas Mattsson-Carlgren is part of the Clinical Memory Research group, a leading centre in the development and evaluation of novel biomarkers for Alzheimer’s disease. In this podcast episode, he discusses why biomarker research is key not only to detecting but also

https://www.multipark.lu.se/article/meet-our-scientists-podcast-niklas-mattsson-carlgren-about-biomarkers-and-future-alzheimers - 2025-11-17

With over 15 research groups dedicated to Alzheimer’s disease research, MultiPark’s goal is to understand the origins of the disease, develop early diagnostics, and improve treatments. The multidisciplinary approach sheds light on the disease from several angles, bridging basic research with clinical investigations. Here are five projects. September is World Alzheimer’s Month. Globally, around 40

https://www.multipark.lu.se/article/alzheimers-awareness-five-research-projects-shaping-future-understanding-diagnosis-and-care - 2025-11-17

For decades, large stretches of human DNA were dismissed as ‘junk’ and considered to serve no real purpose. In a new study in Cell Genomics, researchers at Lund University in Sweden show that the repetitive part of the human genome plays an active role during early brain development and may also be relevant for understanding brain diseases. DNA carries the complete set of instructions an organism

https://www.multipark.lu.se/article/why-repetitive-dna-matters-human-brain-evolution-and-disease - 2025-11-17

Enormous amounts of data about Alzheimer’s Disease have been generated from clinical studies so far. Still, the molecular drivers of Alzheimer’s Disease are largely unknown. With the TAU-TIME project, Jacob Vogel aims to advance knowledge by developing an AI tool that brings together known biological mechanisms with data from patients with the disease. Recent funding from the European Research Cou

https://www.multipark.lu.se/article/time-unite-lab-and-clinic-15-million-eu-build-ai-model-alzheimers-disease - 2025-11-17

Early diagnosis is key to receiving proper care and advancing research on future therapies for neurodegenerative diseases such as Parkinson’s and dementia with Lewy bodies. New research from Skåne University Hospital and Lund University shows that combining a simple smell test with advanced spinal fluid analysis can predict these diseases with high accuracy, while sparing nearly half of patients f

https://www.multipark.lu.se/article/smell-test-cuts-need-invasive-parkinsons-screening - 2025-11-17

Researchers at Lund University in Sweden have developed a digital cognitive test for diagnosing Alzheimer's disease that is intended for use in primary care. “This digital test, which patients perform on their own with minimal involvement from healthcare personnel, improves the primary care physician's ability to determine who should be further examined by blood tests for Alzheimer's pathology ear

https://www.multipark.lu.se/article/new-digital-cognitive-test-diagnosing-alzheimers-disease - 2025-11-17

What if brain diseases could be cured by turning on the proper genes? Meet our scientist, Professor Cecilia Lundberg! She explains how gene therapy may complement cell therapies to combat Parkinson’s disease. Cecilia Lundberg is head of the CNS Gene Therapy Research Group and has spent her whole career developing cutting-edge tools that may be used in future therapies to slow down or cure neurodeg

https://www.multipark.lu.se/article/meet-our-scientists-podcast-cecilia-lundberg-about-gene-workshop - 2025-11-17

Have you ever wondered what the journey of someone living with Parkinson’s disease looks like? Meet our scientist, Professor Per Odin! He shares his experiences of the bumpy road faced by patients he has supported over the years, both in healthcare and in research studies. Parkinson’s disease is a long, challenging course; one that science works tirelessly to understand, where halting neurodegener

https://www.multipark.lu.se/article/meet-our-scientists-podcast-odin-about-parkinsons-journey - 2025-11-17

In a study led by Lund University and the Amsterdam University Medical Center, researchers used PET to analyse aggregates of tau pathology in more than 12,000 people from all over the world. The study – the largest ever of its kind – examines the connection between genetic predisposition, gender and age in relation to tau pathology in Alzheimer’s disease. The study is published in Nature Neuroscie

https://www.multipark.lu.se/article/largest-ever-taupet-study-alzheimers-deepens-understanding-disease - 2025-11-17

With an approval rate of just 17 %, this year’s Swedish Research Council grants were harder than usual to secure. Still, several of MultiPark’s group leaders were awarded major grants in Medicine and Health 2025. Receiving grants from the Swedish Research Council is seen as a mark of quality and an important step in advancing an independent research group. Recently, five MultiPark researchers were

https://www.multipark.lu.se/article/multipark-scientists-awarded-prestigious-vr-consolidator-grant - 2025-11-17

How do you stop Alzheimer’s disease without a simple way to diagnose it? It’s a real chicken and egg problem, as I wrote last year on TGN. Discovering a treatment for Alzheimer’s requires lots of clinical trials for new drugs—but it’s difficult to enroll participants without a way to identify people who have the disease early enough for potential treatments to work. Read the full article here

https://www.multipark.lu.se/article/unexpected-way-we-might-one-day-diagnose-alzheimers - 2025-11-17